Clarivate Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the lifetime prevalence of AD for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 10 years for the countries covered in this report. In addition to forecasting lifetime prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in high-income countries.
Clarivate Epidemiology’s AD forecast will answer the following questions:
- Of all people diagnosed with AD, how many in each high-income country are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AD over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology forecasts the following patient populations:
- Total prevalent cases of asymptomatic AD.
- Total prevalent cases of symptomatic MCI due to AD by diagnosis status.
- Total prevalent cases of AD.
- Total prevalent cases of AD by severity (mild, moderate, severe).
- Total prevalent cases of AD by diagnosis status.
- Diagnosed prevalent cases of AD by symptom status (agitation, depression, hallucinations).
- Diagnosed prevalent cases of MCI due to AD by drug-treatment status.
- Diagnosed prevalent cases of AD by drug-treatment status.
- Diagnosed prevalent cases of mild AD by drug-treatment status.
- Diagnosed prevalent cases of moderate AD by drug-treatment status.
- Diagnosed prevalent cases of severe AD by drug-treatment status.
… and many more (details available on request).
Note: Coverage may vary by country and region.
Oliver Blandy, M.Sc.
Oliver Blandy, M.Sc., is a senior epidemiologist at Clarivate. Previously, Oliver worked as a research assistant for Imperial College London, where he was the lead for several studies within an NIRH-funded research group investigating healthcare-associated infections and antimicrobial resistance. He holds an M.Sc. from the University of Bristol, where he specialized in nutrition, physical activity, and public health. He also holds a B.Sc. in chemistry and a postgraduate certificate in education, both from the University of Bristol.
Nishant Kumar, M.P.H.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.